4.4 Article

Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series

Journal

HUMAN PATHOLOGY
Volume 119, Issue -, Pages 69-78

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2021.11.004

Keywords

Adenocarcinoma; Augmentation cystoplasty; Ileal conduit; Bladder; Urologic reconstruction

Categories

Funding

  1. Vanderbilt Institute for Clinical and Translational Research, CTSA by the National Center for Advancing Translational Sciences [UL1 TR002243]

Ask authors/readers for more resources

This study evaluates the clinicopathological features of secondary tumors arising after urologic reconstruction procedures. The study includes 11 cases with an average age of 51.7 years and a male-to-female ratio of 8:3. The tumors are mostly adenocarcinomas, presenting late and behaving aggressively.
Urinary diversion and reconstructive urologic procedures are most often performed by incorporating various intestinal segments into the urinary tract. Although the risk of malignancy, among other complications, is well recognized and occurs most frequently after ureterosigmoidostomies and cystoplasties, data on the histopathologic and immunohistochemical characteristics of these tumors are scant. This study aims to evaluate the clinicopathological features of secondary tumors arising after urologic reconstruction procedures. Eleven cases were identified among five collaborating academic institutions. The average age was 51.7 years, and the M:F ratio was 8:3. Surgical procedures included 7 ileal conduits, 2 gastrocystoplasties, 1 augmentation cystoplasty not otherwise specified (NOS), and 1 Indiana pouch. Median time from reconstruction to malignancy was 36 years. Malignancy included adenocarcinoma in 10 patients (intestinal type in 6, gastric in 2, signet-ring cell in 1, undetermined type after neoadjuvant treatment in 1) and squamous cell carcinoma in 1. By immunohistochemistry, the adenocarcinomas were CK7 (45%), CK20 (89%), CK903 (78%), CDX2 (89%), SATB2 (67%), and betacatenin (100%) positive. GATA-3 was negative in all cases. Pathologic stage was Ti (30%), T2 (40%), T3 (20%), and T4 (10%). Regional lymph node and distant metastasis were present in 60% and 20%, respectively. Treatment included multimodality therapy in most patients. On follow-up (mean, 27.4 months), 2 patients were dead (1 of disease), 3 were alive with disease, 4 were alive without disease, and 2 were lost to follow-up. Secondary malignancy arising within urologic reconstruction is rare, most frequently has adenocarcinoma morphology, presents late, and behaves aggressively. (C) 2021 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available